Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.32 USD | -3.60% | +0.12% | -11.71% |
07:00pm | GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines | MT |
06:40pm | GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines | MT |
Financials (USD)
Sales 2024 * | 59.96B | Sales 2025 * | 62.57B | Capitalization | 149B |
---|---|---|---|---|---|
Net income 2024 * | 6.75B | Net income 2025 * | 9.29B | EV / Sales 2024 * | 3.27 x |
Net Debt 2024 * | 47.04B | Net Debt 2025 * | 41.91B | EV / Sales 2025 * | 3.05 x |
P/E ratio 2024 * |
19.3
x | P/E ratio 2025 * |
14
x | Employees | 88,000 |
Yield 2024 * |
6.46% | Yield 2025 * |
6.62% | Free-Float | 59.09% |
Latest transcript on Pfizer, Inc.
1 day | -3.25% | ||
1 week | +0.20% | ||
Current month | -8.32% | ||
1 month | -7.25% | ||
3 months | -7.39% | ||
6 months | -17.21% | ||
Current year | -11.64% |
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 22-05-01 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 20-03-31 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 17-02-22 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 13-09-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.74% | 215 M€ | +12.51% | - | |
9.37% | 18 M€ | +3.04% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 25.4 | -3.29% | 23 167 395 |
24-04-24 | 26.27 | -0.19% | 24,547,780 |
24-04-23 | 26.32 | +0.23% | 24,297,821 |
24-04-22 | 26.26 | +1.00% | 35,678,657 |
24-04-19 | 26 | +2.40% | 38,372,801 |
Delayed Quote Nyse, April 25, 2024 at 01:01 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.64% | 149B | |
+24.17% | 562B | |
-6.40% | 358B | |
+19.41% | 322B | |
+8.27% | 297B | |
+13.45% | 219B | |
+6.04% | 199B | |
-10.51% | 196B | |
-6.46% | 146B | |
+2.07% | 117B |
- Stock Market
- Equities
- PFE Stock